Two-drug study for returning childhood solid tumors
Part of Cancer clinical trials.
This study tests a combination of two drugs, MM-398 and cyclophosphamide, for children and young adults whose cancer has come back or not responded to earlier treatment. The goal is to find the best dose and see how well it works against certain tumor types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 and 21 years old.
- You need a diagnosis of Ewing sarcoma, rhabdomyosarcoma, neuroblastoma, or osteosarcoma.
- Your cancer must have grown or returned after previous treatment.
- Your tumor must be measurable or visible on imaging tests.
- Your bone marrow, liver, and kidneys must be working well enough.
- You must have recovered from the side effects of earlier treatments and have no other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
This trial tests a combination of two drugs (eflornithine and AMXT 1501) for children and young adults with certain types of cancer that have relapsed or not responded to standard treatment, or for a specific brain tumor (DIPG) at diagnosis. The goal is to see if this drug pair is safe and effective.
This study tests a combination of two drugs, cabozantinib and ifosfamide, for sarcomas that have come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
This study is testing new drugs for young people (ages 10 and up) with Ewing sarcoma or related tumors that have come back or stopped responding to treatment. The goal is to find promising drugs that may help shrink tumors or slow their growth.
Hear when a new Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.